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Abstract Molecular dynamics simulations can now track
rapid processes—those occurring in less than about a
millisecond—at atomic resolution for many biologically
relevant systems. These simulations appear poised to exert
a signiﬁcant impact on how new drugs are found, perhaps
even transforming the very process of drug discovery. We
predict here future results we can expect from, and
enhancements we need to make in, molecular dynamics
simulations over the coming 25 years, and in so doing set
out several Grand Challenges for the ﬁeld. In the context of
the problems now facing the pharmaceutical industry, we
ask how we can best address drug discovery needs of the
next quarter century using molecular dynamics simula-
tions, and we suggest some possible approaches.
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Introduction
Understanding the mechanisms underlying the behavior of
chemical and biological systems requires scrutiny at spatial
and temporal resolutions that challenge current experi-
mental techniques. Molecular dynamics (MD) simulations
are being increasingly partnered with experiments in this
quest because simulations can track system behavior across
a vast spatiotemporal domain—length scales up to thou-
sands of a ˚ngstro ¨ms, with atomic precision, and timescales
up to milliseconds, at femtosecond resolution. This power
of simulations has been further increased by recent meth-
odological advances. Here, we predict what the next
25 years of MD simulations may bring, especially regard-
ing their application to the search for new drugs.
Novel computational methods, including MD simula-
tions, have assumed an ever growing role in drug discovery
overthepastquartercentury.Yet,despitehavinglearnedand
contributed much, we face many challenges ahead. To take
novel computational methods to the next level—such that
they radically alter the very landscape of drug discovery—
we must grapple with those challenges and rise above them.
This essay is meant to be thought provoking—we raise
more questions than we answer. It is arranged such that the
knowledgeable reader can easily skip to the parts of
interest. We begin by reviewing the challenges, using any
technique, including computational ones, in ﬁnding new
drugs. Next, we compare the computational state of the art
of 25 years ago with that of today, with a particular
emphasis on MD simulations. Following brief comments
on the nature of innovation and the art of making predic-
tions, we make a series of straightforward predictions on
the future directions of MD simulations, including partic-
ular ways simulations might be used in drug discovery;
some key methodological improvements we believe will be
needed for success are discussed. We then turn our atten-
tion to several ‘‘Grand Challenges’’ for the ﬁeld, including
a rather audacious goal on how simulations might be used
in drug discovery. We conclude with our thoughts on how
MD simulations are perceived by the larger scientiﬁc
community, and on the importance of setting goals.
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Computational chemistry methods have become deeply
integrated into drug discovery over the past 25 years [1,
2], expanding signiﬁcantly beyond early work on quanti-
tative structure–activity relationships (QSAR) [3], com-
puterized chemical structure representation [4], and
computerized compound, reaction, property, and struc-
ture–activity databases [5]. Indeed, computational methods
have become so much part of the very fabric from which
new drugs are woven—simply ascertaining their speciﬁc
impact is quite difﬁcult—that their continued role in drug
discovery has been questioned as the pharmaceutical
industry faces looming scientiﬁc and economic challenges.
It is thus prudent to ask whether we are focusing our
efforts where they yield the most beneﬁt. Are we
addressing the key challenges facing the pharmaceutical
industry?
Productivity is one of the most signiﬁcant challenges
facing the pharmaceutical industry, with $50 billion spent
annually to produce only *20 new drugs [6]. Ever-shifting
organizational structures hamper success [7–9], but the root
problem is simply that most new drug projects fail—only
*3% of projects ever produce a marketed drug. It is cru-
cial to understand at what stage in the pipeline projects fail,
for what reasons, and then to ask how computational
approaches can help avert those failures.
Drug discovery—the focus of most computational
chemistry efforts—is tolerably successful but needs
improvement: about 35% of discovery projects succeed, on
average, in delivering experimental drugs ready for clinical
testing. The project stages of target identiﬁcation and
screening, hit-to-lead, lead optimization, and preclinical
candidate selection have individual success rates ranging
from 69 to 85% [10]. When discovery projects fail, they
fail for diverse reasons, notably unclear target biology, lack
of appropriate leads, poor potency or selectivity, inappro-
priate drug-like properties, lack of efﬁcacy, and unexpected
animal toxicity.
Clinical development success rates, however, present a
stark contrast, as do the more uniform reasons for clinical
failure. An experimental drug entering a Phase I clinical
trial has only a 10% chance of reaching the market: the
success rates in each of the three trial Phases and for ﬁnal
regulatory approval are just 54, 34, 70, and 91% [10]. As to
the reasons:
Lack of clinical efﬁcacy has meanwhile become the
most frequent cause for discontinuation of a drug
development program. Consequently, attrition rates
are highest in clinical Phase II, which usually
includes the ﬁrst evidence for pharmacodynamic
action of the compound or, proof of concept. [11]
Two-thirds of recent Phase III failures are due to inad-
equate efﬁcacy [12], as are more than half of Phase II [13]
and *16% of Phase I [14] failures. Toxicity and business-
related failures (which often are due to inadequate efﬁcacy,
e.g. compared to competitive or existing drugs) contribute,
but much less so. Poor pharmacokinetic properties, once a
major issue, now account for just *10% of clinical fail-
ures, mostly in Phase I [15], a gratifying result of the
increased attention paid to these critical properties during
lead optimization. The bottom line is this: All experimental
drugs enter human clinical trials based on extensive pre-
clinical data indicating that they should work; most none-
theless do not, defying our well-grounded expectations.
The complexities of human biology, ampliﬁed by the
limitations of the reductionist paradigm of target-based
drug discovery [16], thus appear to be our industry’s largest
challenge.
We believe that computational chemistry methods—and
in particular MD simulations—should reasonably be
expected to signiﬁcantly impact the trajectory of the
pharmaceutical industry. Better success in clinical trials
will come, in part, with an increased understanding of
human biology, and simulations will increasingly make
useful contributions here. Arguably, however, we should
continue to focus our greatest efforts on early drug dis-
covery: The problems there align especially well with
potential computational solutions, and addressing those
problems will reduce the signiﬁcant resources—about 15
discovery projects on average—devoted to achieving a
single product launch. Indeed, despite discovery enjoying
triple the success rate of development, parametric sensi-
tivity analysis highlights lead-optimization costs as the
third-most important factor (after Phase II and III trial
success rates) that dictates overall success in bringing a
drug to market [10], an argument supported as well by a
related analysis [17]. Improving our ability to select and
design better molecules at all discovery stages, including
lead optimization, is an achievable and valuable goal. We
believe this discovery focus, by helping both to reduce the
needed resources and to increase clinical candidate quality,
may also bring signiﬁcant indirect savings: the really big
payoff may be a resultant improvement in clinical trial
success rates.
25 years ago in JCAMD
What was the state of computational chemistry in drug
design 25 years ago? Perusing early JCAMD issues
reveals, perhaps surprisingly, that many of the pressing
questions then are still of interest today, and many methods
then new have become our methods of choice. What has
changed—dramatically—is both our conﬁdence in, and our
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computations.
Ligand-based approaches were used, for example in the
three-dimensional pharmacophore modeling of benzodiaz-
epine receptor ligands [18], and to design nicotinic ago-
nists using a shape matching algorithm [19]. Quantum
mechanics (QM) calculations revealed an angiotensin-
converting enzyme inhibitor QSAR [20]. The solution
conformational energies of apomorphine analogues were
correlated with their biological activities [21]. Many such
conformational analyses used molecular mechanics (MM),
for instance Allinger’s MM2. MD simulations had pro-
gressed from the ground-breaking 9 ps in vacuo simulation
of bovine pancreatic trypsin inhibitor [22] to encompass
solvated proteins, lipids, and ion channels [23]. The
determination of free energy differences using MD
simulation-based thermodynamic cycle integration was
reviewed [24]; within a year, free energy perturbation was
used to compute the relative binding free energies of an
antiviral compound to wild-type and drug-resistant human
rhinovirus [25]. All of these methods, in their original or in
enhanced forms, are widely used today; MD simulations in
particular have advanced dramatically.
Molecular dynamics—the current state of the art
Molecular dynamics simulations are used today to study
nearly every type of macromolecule—proteins, nucleic
acids, carbohydrates—of biological or medicinal interest.
Simulations span wide spatial and temporal ranges and
resolutions. In explicit, all-atom MD, thousands to millions
of individual atoms representing, for instance, all the atoms
of a protein and surrounding water molecules, move in a
series of short (e.g., 2 fs), discrete time steps. At each step,
the forces on each atom—determined from the ‘‘force
ﬁeld,’’ a collection of physics-based parameters that rep-
resent both bonded and non-bonded (e.g., van der Waals)
inter-atomic forces—are computed and the atomic position
and velocity are updated according to Newton’s laws of
motion [26]. This process is repeated billions of times to
provide continuous atomic trajectories lasting as long as
1 ls, or even longer. The examples below indicate some of
the current capabilities of MD simulations and the insights
they can provide. Additional examples may be found in a
recent review on the use of MD simulations in drug dis-
covery [27].
The biological systems studied using all-atom MD
simulations can be very large, comprising millions of
atoms. For instance, several such simulations of bacterial
ribosomes—the pivotal RNA/protein complex that is the
target of diverse antibiotics—have been carried out. In a
recent example, comprising *3.2 million atoms, the
‘‘accommodation’’ motion of the ribosome that allows
aminoacyl-tRNA binding was studied [28]. Simulations of
satellite tobacco mosaic virus (STMV; *1 million atoms)
recapitulated the known stability of the complete virus and
of the RNA core particle [29]. The simulations further
indicated that empty STMV capsids exhibit a pronounced
instability, a new ﬁnding that explained the failure of
experimental efforts to prepare such empty capsids. An
impressive effort to further increase the scale of MD sim-
ulations is now using 100 STMV particles—100 million
atoms—as the test system [30].
MD simulations are well-suited to the study of mem-
brane proteins, which present particular challenges for
experimental methods. For instance, the control of ion
channel conductance, so-called ‘‘gating,’’ has been studied
for many channels, among them the nicotinic acetylcholine
receptor. Beckstein and Sansom used MD simulations and
potential of mean force calculations to determine the free-
energy barrier to ion passage through the central pore of the
nicotinic receptor [31]. They found an *10 kT barrier to
ion passage in the constricted state, in which the hydro-
phobic central pore is dewetted, sufﬁciently high to account
for effective channel closure. Their mechanistic results
likely apply to the entire ‘‘Cys-loop’’ superfamily of
ligand-gated ion channels, of which the nicotinic receptor
is a much-studied prototype; these results also heralded
hydrophobic gating in the structurally distinct voltage-
gated ion channel superfamily [32].
Free energy calculations of ligand–receptor binding is a
natural application of simulations in drug discovery. Sev-
eral approaches have been used. Grand canonical Monte
Carlo simulations can identify both potential ligands and
their binding site(s) on the drug target [33]. In essence, the
target is ﬂooded with ligands, or more typically small
fragments, which are then slowly ‘‘evaporated,’’ leaving
behind only the most tightly bound ligands. This method
has proven successful in a few cases, for instance, in the
design of novel nanomolar inhibitors of p38 kinase [34].
High throughput molecular mechanics with Poisson–
Boltzmann surface area (MM-PBSA) was used at Abbott
Laboratories to directly estimate relative binding free
energies for 308 ligands drawn from three representative
drug discovery projects—the protease urokinase, the
phosphatase PTP-1B, and the kinase Chk-1 [35]. The
results were encouraging both for the number of ligands
evaluated and the target scope, but the moderate correla-
tions between predicted and experimental binding free
energy values (r
2 = 0.52–0.69) suggest that the fast MM-
PBSA method is insufﬁciently accurate, by itself, to guide
a medicinal chemistry program.
Alchemical methods yield improved quantitative results
at the cost of signiﬁcantly more computation [36]. The
Jorgensen group’s work on non-nucleoside HIV reverse
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recent example. Compound design decisions were based, in
part, on calculated estimates of binding free energy dif-
ferences, determined using free energy perturbation with
Monte Carlo sampling, among various Cl-substituted test
compounds [37]. This optimization strategy has provided
novel aminotriazines, possessing cellular EC50 values
below 10 nM, effective against both wild-type HIV-RT
and the resistant Tyr181Cys variant [38]. Using the same
method, a 5 lM virtual screening hit was transformed into
a 55 pM inhibitor, apparently the most potent NNRTI
reported to date [39]. The results obtained thus far on HIV-
RT are quite encouraging, and the utility of this approach
in other systems is an area of active investigation.
The process by which drugs bind to receptors has been
studied in several systems. Benzamidine bound spontane-
ously to trypsin in MD simulations, achieving a good
match to the crystal-structure–deﬁned pose and revealing
the binding pathway [40]. The unbiased binding of kinase
inhibitors [41] and G protein–coupled receptor (GPCR)
agonists [42] and antagonists [43] has also been demon-
strated. For example, the endogenous cannabinoid sn-2-
arachidonoylglycerol was found to enter the binding pocket
of a CB2 receptor homology model from the lipid bilayer
[42]. Notably, simulations of several b-blockers and a
b-agonist binding to two b-adrenergic receptors revealed
where along the binding pathway dehydration of the ligand
and receptor—long known to a major source of ligand
afﬁnity—occurs [43]. The work further hinted that dehy-
dration presents an unexpected kinetic barrier to binding,
leading to suggestions on how ligand/receptor dehydration
might be modulated to affect drug binding and unbinding
kinetics.
Several related techniques leverage the power of atom-
istic MD simulations, extending the range of problems that
can be studied. Coarse-grained simulations allow one to
sacriﬁce spatial detail to achieve longer, more biologically
relevant timescales, thereby enabling the study of processes
that currently are too slow, or of systems too large, to study
with atomistic simulations [44, 45]. This approach enabled,
for example, the simulation of the assembly of apolipo-
protein A-I and lipids into discoidal high-density lipopro-
tein (HDL) particles [46], and similarly the self-assembly
of membrane proteins into lipid bilayers [47]. Several
distinct, atomistic approaches aim to accelerate the still-
insufﬁcient sampling of protein conformational states, for
example metadynamics [48], accelerated MD [49], and
temperature accelerated MD [50].
Our group has recently shown, using a specialized
supercomputer designed especially for MD simulations,
named Anton [51], that all-atom MD simulations can
now reach timescales on which much interesting biology
occurs. One millisecond-long, continuous single-trajectory
simulations of small globular proteins, for instance bovine
pancreatic trypsin inhibitor (58 amino acids) [52] or the
fast-folding N-terminal fragment of ribosomal protein L9
(39 amino acids) [53], have been performed. Such simu-
lations take a few months of elapsed time. Much larger
systems (e.g., receptor tyrosine kinases, GPCRs, or volt-
age-gated ion channels, all embedded in lipid bilayers,
totaling C10
5 atoms) can be simulated for hundreds of
microseconds, with aggregate simulation times[1 ms.
These simulations have demonstrated the de novo
folding of proteins, long recognized as an important
problem in biophysics [54]. Initial work has focused on
fast-folding proteins, for instance the WW domain protein
FiP35; WW domains, which comprise a three-stranded
b-sheet arranged as two b-hairpins, bind proline-rich
sequences. Fip35 folds with an experimental time constant
of 14 ls[ 55], making it the fastest-folding WW domain
known when our work began; this rapidity has made it an
attractive simulation target [56, 57]. In our simulations of
Fip35—initiated from the extended state—the protein
achieved the folded state, with a backbone root-mean-
squared deviation (RMSD) of *1A ˚ from the crystal
structure [52]. The simulations were carried out under
conditions where the folded and unfolded states exist in
reversible equilibrium; repeated folding/unfolding barrier
crossings followed a single well-deﬁned pathway, with
kinetics that closely match experiment. Elucidation of the
folding transition state allowed an even faster-folding
Fip35 variant to be designed, which was subsequently
conﬁrmed experimentally [58]. These folding results have
been extended to encompass 12 small proteins of diverse
structure—a-helical, b-sheet, and mixed a/b—with 8 of the
12 proteins reaching RMSD values less than 2 A ˚ from the
respective crystal structure [53]. It is noteworthy that all 12
of these folding simulations used a single, physics-based
molecular mechanics force ﬁeld—a modiﬁed version of the
CHARMM force ﬁeld [59]—indicating an increased level
of accuracy that enables simulation of large conformational
changes.
The art of making predictions
Making predictions is hard, and, as Niels Bohr famously
said, it becomes especially difﬁcult when we seek to pre-
dict the future. The varied forms that technological
advances take suggest why this is so: Innovations range
from obvious extrapolations beyond current practice, to
unexpected new technologies or experimental ‘‘We’re not
sure what this is good for…’’ ideas, to active, purposeful
invention of the future. Innovations also vary dramatically
in impact. Most are incremental advances, with predictable
effects. The effects of ‘‘disruptive’’ innovations, which
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very few innovations are truly ‘‘revolutionary’’—they alter
life in manifold, unforeseeable ways.
A brief history of the computer age illustrates these
points. Computers permeate modern life in ways that
would rightly be viewed as revolutionary a century ago.
The underlying technology, the transistor, was itself the
result of experimentation and purposeful invention. The
transistor is both a disruptive innovation—a new approach
to electronic switching that displaced the relays and vac-
uum tubes of early computers—and a revolutionary inno-
vation: It enabled creation of the integrated circuit, thus
launching the dramatic ‘‘Moore’s law’’ increases in com-
putational power. This trend, which relies upon continuous
innovation, often incremental, and an intentional drive to
achieve a now self-fulﬁlling prophesy, has enabled the
tremendous computational advances upon which all areas
of human endeavor—including computer-aided molecular
design—have become so reliant.
This history exhibits both the determination of Edison—
he said the light bulb was ‘‘one percent inspiration, ninety-
nine percent perspiration’’—and Alan Kay’s belief that the
best way to predict the future is to invent it. For our task
here, the import of this history is that it seems largely
obvious in hindsight, and yet it would have been very
difﬁcult, if not impossible—say, for Shockley, Brattain,
and Bardeen, in 1947—to predict.
Molecular dynamics—predictions for the
next 25 years
Computer power has tremendously increased in the past
25 years. Many studies from 1987 were performed on
Digital Equipment Corporation VAX 11/780 computers
(1978, *0.0001 GFLOPs); the rhinovirus study mentioned
above [25] used a Cray X-MP (1982, 0.4 GFLOPs). Today,
personal computers far more powerful are commonplace
(2011 Intel Core i7, *110 GFLOPs), and most MD sim-
ulations are run on commodity clusters (teraFLOPs). Su-
percomputers such as IBM’s Blue Gene/L (2005, 0.3
petaFLOPs), deliver greater performance on diverse tasks.
Tailoring the hardware to a speciﬁc task—MD simulations,
for instance—enables even higher performance: the Anton
supercomputer we created [51] increases the speed of indi-
vidual MD simulations by nearly two orders of magnitude.
Computational power in the year 2037 may be as much
as one million-fold greater than it is today. We make
several assumptions: Continuation of Moore’s law—not
unreasonable in light of current industry 15-year projec-
tions and a 50-year history of surmounting technological
hurdles—suggests that processor computational power
may increase as much as one thousand-fold. Enhanced
processor integration, and architectural and software
advances (including MD-speciﬁc algorithmic improve-
ments), will yield further increases. Using ever more pro-
cessors in parallel will compensate for limits in individual
processor performance; such computers, like Anton, will
increasingly favor very much larger, rather than very much
longer, simulations. Given these considerations, what are
some implications of such large increases in computational
power, both for MD simulations in general, and for the use
of simulations in drug discovery?
Simulations will become much larger and will reach
longer timescales. Today’s not atypical simulation size, a
box 100 A ˚ on each edge—a volume of 10
-6 lm
3—might
scale up to 1 lm
3, the volume of Haemophilus inﬂuenzae,a
small bacterium. Of course, simulating an entire bacterium
for a millisecond or so probably wouldn’t teach us much, in
part because of the limited diffusion of individual macro-
molecular assemblies on this timescale. Smaller simulations
comprising a substantial fraction of a cell (e.g., RNA
polymerase with associated transcriptional factors), how-
ever, on biologically signiﬁcant timeframes such as one
second(i.e., long enough to transcribe a small gene),may be
feasible. This reach for ever larger and longer simulations
will also be increasingly aided by improved algorithmic
methods to increase the sampling of conformational space.
We predict that we will determine, computationally, the
three-dimensional folded structure of proteins from their
amino acid sequence. Put another way, we will be able to
observe the Central Dogma of molecular biology—
DNA ? RNA ? protein—using simulations. Atomistic
MD simulations have already demonstrated today the de
novo folding of small (up to 80 residues) protein domains.
The effect of force ﬁeld quality on folding was mentioned
[59]; it seems likely that continuous force ﬁeld improve-
ment (see below) will enable further progress. With those
caveats, extrapolation suggests that folding of more typical
(*300 residue) single-domain proteins ([10 ms simula-
tions of *10
5 atoms) will be feasible within 10 years.
Folding of large, multi-domain proteins—for instance,
b-galactosidase, comprised of four 1,024-residue, ﬁve-
domain subunits—will likely be accessible within 25
years. Beyond delivering folded structures, useful in their
own right, especially in drug discovery, simulations will
help us to understand basic folding mechanisms. Our hope
is that by folding many proteins using a physics-based
approach, these simulations will ‘‘provide the data for
developing abstract models at a conceptual level that
describe general and unambiguous features of the protein-
folding mechanisms’’ [60]; brute force folding simulations
might then no longer be needed, thereby increasing our
capabilities even further.
A beneﬁt of our ability to fold proteins will be that
structure-guided drug design can be extended to new
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or NMR structure is available, or for which the available
structures are perhaps not in a biologically relevant form.
More signiﬁcant, perhaps, will be those mis-folded or
aggregated proteins—especially prions, amyloidogenic
proteins, and intrinsically disordered proteins (which often
partially fold on binding a partner)—that are thought to
underlie major diseases, for instance Alzheimer’s disease.
The tractability of targeting these proteins will be increased
if we can, for example, observe computationally both the
atomic details of their (mis)folding and the modulating
impact of candidate drug molecules.
Of great interest will be the computational assembly of
interacting macromolecules. It is increasingly clear that
macromolecule–macromolecule interactions drive much of
biology: the sheer number of pairs, or larger assemblies, of
macromolecules—and hence their regulatory capacity—far
exceeds the limited number of individual human gene
products (\25,000). In accord with this notion, the unbi-
ased assessment of protein–protein and protein–nucleic
acid interactions, in particular, will present new drug dis-
covery opportunities. Nature seems to have already lever-
aged this key aspect of biology—many natural product
drugs and signal mediators bind at macromolecule–mac-
romolecule interfaces [61]—and we are beginning to catch
on with some synthetic and natural product-derived anti-
biotics and anti-cancer agents that bind at, and stabilize,
interfaces among and between proteins and nucleic acids.
MD simulations can address two aspects of this problem.
First, how and where do the partners interact? And as they
interact, are novel ligand binding sites created, at the
interface or at allosteric sites? MD simulations seem to be
good at identifying low-energy protein conformations that
harbor cryptic drug binding sites [27]. Second, how can
small molecule ligands modulate those interactions? How
can we optimize their binding and drug-like properties?
Simulations of macromolecular assembly will also
extend to include very large complexes, such as the nuclear
pore complex or even entire organelles. It should be pos-
sible, for example, to observe the passage of cargo proteins
as they transit through the nuclear pore. Intentional mis-
assembly of complexes, for instance of bacterial ﬂagella or
viral capsids, again presents opportunities for the targeting
of new drugs. We also think that simulations of enzyme
catalytic cycles, complete with bond making and breaking,
will become much more common, enabled by methodo-
logical improvements that accelerate QM/MM simulations.
Putting these predictions into practice
These predictions—really just straightforward extrapola-
tions—rest on a few key assumptions. We mentioned raw
processor computational power above. The semiconductor
industry, having hit some fundamental barrier, may at some
point cease to deliver. Gordon Moore has bet against his
own law several times; he has, however, each time been
wrong. We think it likely that the innovative spirit of
device architects, coupled with one or more cutting edge
technologies that are published in science journals today
but will be discussed in engineering journals tomorrow,
will prevail. More within the control of the computational
chemistry community are some clear improvements we
need to make, or in some cases adopt now, in how we carry
out MD simulations, especially with regard to force ﬁelds.
Lou Allinger recently made a compelling case for
carefully crafted small-molecule molecular mechanics
force ﬁelds, such as MM4, in the prediction of molecular
structure [62]. We believe that MD simulations would
beneﬁt from use of analogous, necessarily more-complex
force ﬁelds. MM4 is a so-called ‘‘Class 3’’ force ﬁeld—it
includes all signiﬁcant off-diagonal force matrix (‘‘cross’’)
terms—making it more complicated, and more realistic,
than the typical, ‘‘Class 1’’ diagonal force ﬁelds used in
MD simulations. The MMFF94 force ﬁeld, widely used for
drug-like molecules because of its broad parameterization
[63], is similar in spirit to MM4, although it uses point
charges (like most widely used MD force ﬁelds) rather than
induced dipoles. Although we have been able to simulate—
on millisecond time scales—processes as complex as small
protein folding and ion permeation through channels using
(tweaked [59]) Class 1 force ﬁelds, we will reach a point
soon where we must be more realistic in our modeling.
Two salient examples are how force ﬁelds handle nucleic
acids and (especially divalent) cations. Another example is
modeling of cation-p interactions [64]. These interac-
tions—driven by electric quadrupole moments and polari-
zation effects—are now recognized to be quite important to
both protein structure (e.g., arginine–tryptophan ladders)
and protein function, for instance, in a wide variety of
protein–ligand interactions [65]. Similarly, London dis-
persion forces between hydrogen atoms—which appear to
contribute signiﬁcantly to the energetics of branched and
strained alkanes [66]—may impact ligand–receptor binding
energetics as well.
Polarizable models should enable us to more accurately
describe (inter)molecular interactions, and indeed several
polarizable force ﬁelds have begun to demonstrate their
value. The AMOEBA force ﬁeld, for instance, includes
some cross terms and, signiﬁcantly, polarizable atomic
multipoles (up to quadrupoles) replace ﬁxed partial charges
[67]; the QMPFF3 force ﬁeld uses similar functional forms
[68]. The two differ in parameterization strategy (chemi-
cally sensible groups versus individual atom types,
respectively). AMOEBA-based simulations performed well
in the recent SAMPL2 hydration free energy challenge
sponsored by OpenEye [69]. Simulations using QMPFF3
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aromatic–aromatic interactions in the gas, liquid, and solid
phases [68], and most notably in ligand–receptor relative
free energy binding calculations (average r
2 = 0.9) [70].
Force ﬁelds such as these will see widespread use.
Here are a few other possible areas for improvement,
which inprincipleshouldimproveMDsimulationaccuracy:
• Simple ﬁxes—for example, improved van der Waals
combining rules, such as those of Waldman and Hagler
[71]—should be evaluated, as should replacement of
point charges by smeared charges of some form (e.g.,
multipoles, exponentials, Gaussians). The use of more
accurate van der Waals and charge models may remove
the need for complicated, and effectively arbitrary,
torsional potentials.
• Constant pH simulations should become standard. The
current approach—multiple simulations launched from
distinct, unchanging protonation states—models reality
poorly. Both implicit solvent (e.g., [72]) and explicit
solvent (e.g., [73]) approaches currently afford compa-
rable results for test proteins such as hen egg white
lysozyme. The explicit approach may prove more
robust in the end. Nature takes advantage of the
diffusion of protons through water [74], and so
should we.
Molecular dynamics—grand challenges
Grand Challenges are goals that, if achieved, will have
revolutionary impact. We present here several such goals
we believe to be worthy of signiﬁcant effort.
Free energy calculations must become reliable and
rapid, for both macromolecule–ligand and macromolecule–
macromolecule interactions. The importance of free energy
to every aspect of drug discovery cannot be overempha-
sized [75]: free energy dictates, for instance, the strength of
interactions, accessible macromolecule and ligand confor-
mations, drug binding both to targets and to anti-targets,
and passive and active drug transport properties. For free
energy calculations to be of consistent use in a drug dis-
covery environment—particularly for quantitative binding
predictions during lead optimization—we will need to
achieve an accuracy equal to or better than typical exper-
imental binding or activity assays, that is, correct to within
a factor of two (*0.4 kcal/mol). These calculations also
need to be turn-key; automated methods must provide
ligand parameters of quality equivalent to those of the
target (macromolecule) force ﬁeld.
Improving free energy calculations has been hard
because the two key issues—insufﬁcient sampling of
conﬁgurational space, and inadequate force ﬁelds—are
impossible to test independently of each other. If the cal-
culation has not converged, how can one say the force ﬁeld
is at fault, and vice versa? Sampling and convergence will
naturally increase with longer simulation times, but other,
more clever approaches may prove useful or even neces-
sary. The more advanced force ﬁelds of today appear to
work well in limited cases [67, 70], but their generality,
especially in protein–ligand binding, remains unproven.
We believe that the force ﬁeld improvements mentioned
above, or others of a similar or completely novel nature,
should help signiﬁcantly. Converged calculations will
enable rigorous determination of both force ﬁeld accuracy
and the need for speciﬁc force ﬁeld improvements. Cho-
dera and co-authors recently suggested that although the
simulation ‘‘ﬁeld has been extraordinarily productive in
generating new algorithmic ideas and advancing technol-
ogies to facilitate the development of more accurate force
ﬁelds, it has failed to produce an effective set of tools for
the design of small molecules. To do so, it is necessary for
the ﬁeld to begin a shift from a research focus to an
engineering focus’’ [76]. We agree. Blind tests such as the
OpenEye SAMPL challenges [69] will continue to be
especially useful, because they allow us to gauge our
successes and failures in an unbiased manner.
A consequence of accurate free energy calculations:
General protein or ligand design will be achievable. ‘‘What
if I change this atom’’ types of questions, for both small
molecule ligands and macromolecules (e.g., antibody
design) must become completely tractable.
We need much more efﬁcient ways to sample confor-
mational space. Must we track Newtonian dynamics at
femtosecond resolution when the events of interest occur
over, say, milliseconds? Twelve orders of magnitude: that’s
equivalent to tracking the advance and retreat of the gla-
ciers of the last Ice Age—tens of thousands of years—by
noting their locations each and every second. Perhaps we
don’t need to resolve all the fast motions (cf. the widely
used SHAKE algorithm [77], and variants). Through some
kind of clever dynamics or averaging, perhaps there is a
way to ‘‘sample,’’ without bias, conformational space well
enough to gain an full understanding of the biological
phenomena being studied.
Two related examples: We will conduct much larger
simulations—on biologically relevant timescales—in the
coming quarter century. Say we are simulating a mito-
chondrion. Do we really need to compute electrostatic
interactions from one end of it to the other? Likewise,
enormous computational power will be ‘‘wasted’’ on water
molecules. How should we gradate water, for instance—
from near-scale atomistic, QM-like particles to a far-scale
bulk-like phase—correctly and effectively [44]?
In other words, are we simulating biological molecules
in the best way? How much of our current ediﬁce is really
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Windley wrote [78]: ‘‘Cathedrals have one millionth the
mass of pyramids. The difference was the arch. Architec-
ture demands arches.’’ Windley’s math may be off, but his
point is apt. Are we missing the MD simulation ‘‘Arch’’?
The issues raised above are just a few obvious ones,
without current solutions. The ‘‘Arch’’—and with it, that
glorious, open space underneath—awaits someone with
better vision to see it.
The ultimate challenge—put here for completeness,
though it is beyond our 25 year timeframe—is Al Gilman’s
vision:
The premise: Someday there will be a computer
labeled ‘‘A Cell,’’ and it will accurately predict all
details of the behavior of a normal cell, as well as that
perturbed by exogenous regulatory inﬂuences, drugs,
mutations, and so on. I think I still believe the pre-
mise, but my time line for the prediction has expan-
ded considerably. [79]
In the meantime, let us focus our attention on this key
question: ‘‘Which molecule should I make next?’’ This is
the question most important to a medicinal chemist, and it
is the question we can, if we frame our studies carefully,
answer in a useful and timely manner.
The future of molecular dynamics simulations
in drug discovery
Antoine de Saint-Exupery wrote ‘‘As for the future, your
task is not to foresee it, but to enable it.’’ Here is our ﬁnal
Grand Challenge—our Goal:
Create the computational methods to enable in silico
drug design
Drug design is ﬁendishly complex, and the universe of
potential drugs is uncharted. Nearly one billion drug-like
compounds comprising just 13 heavy atoms (C, N, O, F, S)
exist [80], yet less than 70 million compounds, of any size,
have been made. We have, in essence, explored only the
very center of this multidimensional chemical universe—a
universe in which essentially all the volume lies in the
dark, unexplored corners [81]. Our computational chem-
istry tools, impressive and helpful as they are (e.g., shape-
based methods [82]), do not yet provide comprehensive
drug design solutions. If we can advance computation in
drug design to the engineering level it enjoys in the aero-
space, architectural, automotive, and electronics indus-
tries—industries for which simulations are now critical to
success—then we will have unleashed the full power of
computers to complement and enhance our own insights
and intuitions.
All the key computational tools needed to reach this
goal are already used—in nascent form—in drug discovery
programs today. Each of these tools needs sharpening, by
means of algorithmic innovation coupled with thorough
experimental validation. We believe that computational
tools and experimental methods should be used in concert,
each according to its particular strengths. These key com-
putational tools are sketched out below:
• The selection of a drug target or interaction partners in
a particular metabolic or signaling pathway—a critical
step in any project—would be guided by extensive
genetics and bioinformatics input. This approach is
being used today; as genomic information and associ-
ated (non-simulation) computational methods mature, it
will become even more powerful.
• The structure of the target (or target complex), if not
available, would be obtained using folding simulations.
Alternatively, simulations may be used to prepare
homology models as accurate as an experimental
structure.
• Simulations would be used, along with complementary
computational chemistry tools, to identify novel drug
binding sites, including allosteric sites. These simula-
tions may be carried out on the target alone or in the
presence of suitable fragments (cf., current ligand
binding or grand canonical Monte Carlo simulations).
• Fragment libraries would be allowed to bind to the
site(s) of interest. As in current practice, library
construction should be guided by sound medicinal
chemistry principles (e.g., the so-called ‘‘Rule of 3’’
[83]).
• Candidate fragments would be scored using various
methods. A triage scoring function, with little grada-
tion, would be followed by binding free energy
calculations (including of bioisosteres); as noted above,
our ability to rapidly and accurately calculate binding
free energies is critical [75].
• Fragments would be grown [84], and possibly linked
[85], within the binding site. This growing process must
be designed from the outset to produce drug-like
molecules: ligands would be penalized (but not elim-
inated) for falling outside of known molecular descrip-
tor bounds [86, 87]; transformations that increase
molecular diversity could be favored; and the growing
process would be completely synthetically ‘‘aware’’
[88–90]—synthetic tractability must be a given.
• Selectivity would be assessed, in awareness of the
project’s particular pharmacological goals (single or
multiple targets).
• It is crucial that we produce drugs, not simply
inhibitors. Thus, ligands would be scored for ADME
(absorption, distribution, metabolism, excretion) and
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may play a dominant role here, but simulations could
also be used to test directly ligand binding to both
metabolic activators (cytochrome P450 oxidases, as
recently demonstrated [91]; glucuronidases; etc.) and
selected anti-targets (e.g., hERG, P-glycoprotein and
other MDR transporters).
Each of these tools will likely mature at different times
in the coming years. Eventually, all may be linked into an
iterative process, with concommitant ligand–target
dynamics and continual rescoring. Such a process would
proceed in parallel on multiple chemotypes, to compensate
for later attrition. Devising robust, multi-dimensional
optimization processes capable of handling enormous
numbers of candidate ligands—search tree pruning must be
apt, not too soon, not too late—will present signiﬁcant
challenges to extending existing computational synthetic
methods [88].
Achieving this audacious goal will require the combined
efforts of computational scientists and engineers working
hand-in-hand with experimentalists to ensure that these
computational tools, as they become more powerful, truly
address the key issues in drug discovery. The idea is not to
displace experimental methods—after all, aircraft are not
designed by just ‘‘telling’’ a computer to ‘‘do it’’—but
rather to advance computation such that it and experiment
become fully complementary partners in the search for new
drugs.
Achieving wider acceptance of molecular dynamics
simulations
Despite their power, molecular dynamics simulations of
biological systems struggle with two issues of perception
among the broader scientiﬁc community. First, many
experimental biologists and (medicinal) chemists do not
trust that MD simulation results are necessarily correct—
they simply don’t ﬁnd the results compelling in the absence
of thorough experimental validation. Simulations are
received very differently elsewhere, for example in most
engineering ﬁelds, astrophysics, condensed matter physics,
weather and climate prediction, and ﬂuid dynamics. We
rely on and trust computational results in those ﬁelds. New
aircraft, for instance, enter a wind tunnel, if at all [92], only
after extensive, integrated simulations have provided ﬂight-
ready (or nearly so) designs. Do MD simulations really
differ so signiﬁcantly from computational ﬂuid dynamics
(CFD) simulations, and if so, how?
These methodological and epistemological aspects of
computer simulations have been deeply pondered by Eric
Winsberg [93]. The methods of CFD simulations—in level
of detail, in modeling viscosity, in performing numerical
integration—are, in truth, as arbitrary and approximate as
those underlying MD simulations. Quantitatively different,
yes, but impossible to prove qualitatively superior. One key
empirical distinction helped aircraft designers become
convinced decades ago of the correctness and value, and
occasional limitations, of CFD simulations: simulations
could capture the essential phenomena on timeframes
overlapping with wind-tunnel tests. This overlap enabled
CFD simulations to be validated by experiment, and
experimental observations to be explained by, and then
predicted by, CFD simulations. MD simulations of bio-
logical systems are now entering just such an overlapping
timeframe regime—orders-of-magnitude extrapolations are
rapidly becoming a thing of the past. How can we
strengthen, then, our partnerships with experimental col-
leagues to accelerate the improvement of MD simulations
through iterative cycles of predictive simulation and
experimental validation, as was done with CFD simula-
tions? And, how can we better communicate the positive
and reliable aspects of current simulations to the broader
biological and pharmaceutical community?
The second, related, issue has to do with how we tend to
conduct our research. Fifty years ago, John Platt made a
strong case for the practice of what he called ‘‘strong
inference’’—a systematic method of scientiﬁc thinking—in
enabling rapid research progress [94]. Were Platt to look at
MD simulations today, he would likely perceive an over-
emphasis on ever more precise quantitative (but ultimately
unrevealing) measurements rather than qualitative results
that actively disprove alternative hypotheses. Platt put it
this way:
Organic chemistry has been the spiritual home of
strong inference from the beginning. Do the bonds
alternate in benzene or are they equivalent? If the
ﬁrst, there should be ﬁve disubstituted derivatives; if
the second, three. And three it is
19. This is a strong-
inference test—not a matter of measurement, of
whether there are grams or milligrams of the prod-
ucts, but a matter of logical alternatives.
And:
It consists of asking in your own mind, on hearing any
scientiﬁc explanation or theory put forward, ‘‘But sir,
what experiment could disprove your hypothesis?’’
Glance at any current issue of Cell to see exactly what
Platt is talking about—in nearly every paper, multiple,
competing hypotheses are generated, put to the test, and
then discarded on the way toward a higher truth. Are MD
simulations not compelling to some because we, too often,
shy away from this rigorous and, admittedly, grueling way
of conducting science? Should we be doing more predict-
ing, and (computational or experimental) testing, and less
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ment that enables things previously unseen to be seen
demands surveys—MD simulation has been rightly called a
‘‘computational microscope.’’ But, surveys cannot continue
for long—rapid progress in science comes from formulat-
ing and rigorously testing hypotheses.
On goals
Two closing thoughts regarding goals. First, as we set
future goals for MD simulations, others will not be stand-
ing still—alternative approaches will also advance, raising
the bar for our success higher than we might now think.
The Rosetta molecular modeling approach, for instance,
has proven to be very powerful (see, e.g., [95, 96]). For
now, this approach is complementary to physics-based MD
simulations, but this may not always be true—one
approach may prove to be simply more effective than the
other. And, in the pharmaceutical arena, the next quarter
century may bring signiﬁcant advances in alternative
therapeutic approaches for which MD simulations have less
to offer. It is not so far-fetched to think that intracellular
antibody delivery or gene therapy—or some unanticipated,
revolutionary innovation—may become commonplace,
decreasing dramatically our dependence on conventional
drugs. We should be mindful of these considerations as we
apply MD simulations in the search for new drugs.
Second, we must set audacious goals. With the dogged
pursuit of goals will come success, even if from unexpected
directions. IBM set out to build a computer that could beat
a grandmaster at chess—and succeeded. They then set their
sights on winning Jeopardy!—and succeeded. We set out
to build a computer that could speed up MD simulations by
orders of magnitude—and succeeded. We have presented a
few audacious goals for the next 25 years; not the best,
perhaps, but a start, because without clear goals to serve as
our guiding star, we are unlikely to succeed. By setting
audacious goals, and by making a plan to achieve them, we
lay a solid foundation for future success.
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